Salix shares slide after FDA requests more data on drug (at bizjournals.com)

slipped Monday after it was revealed that U.S. drug regulators want more information on one of the company's drugs before they will consider approving it for sale. Salix (Nasdaq: SLXP), the Raleigh pharmaceutical company, said late on May 16 that it has received an "approvable letter" from the... [read full story]